Trial Profile
A Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2015
Price :
$35
*
At a glance
- Drugs Ulimorelin (Primary)
- Indications Postoperative ileus
- Focus Adverse reactions
- Sponsors Norgine
- 28 Apr 2015 New trial record